



Article Phytochemical Evaluation of *Terminalia canescens* DC. Radlk. Extracts with Antibacterial and Antibiotic Potentiation Activities against Selected β-Lactam Drug-Resistant Bacteria

Muhammad Jawad Zai^{1,2}, Matthew James Cheesman³ and Ian Edwin Cock^{1,2,*}

- ¹ Centre for Planetary Health and Food Security, Griffith University, Brisbane, QLD 4111, Australia; muhammadjawad.zai@griffithuni.edu.au
- ² School of Environment and Science, Griffith University, Brisbane, QLD 4111, Australia
- ³ School of Pharmacy and Medical Sciences, Griffith University, Southport, QLD 4222, Australia; m.cheesman@griffith.edu.au
- * Correspondence: i.cock@griffith.edu.au; Tel.: +61-737357637

Abstract: Terminalia canescens DC. Radlk. (family: Combretaceae) is native to northern Australia. Species of the genus Terminalia are widely used as traditional medicines to treat diverse ailments, including bacterial infections. However, we were unable to find any studies that had examined the antimicrobial activity of T. canescens. In this study, T. canescens was screened against a panel of bacterial pathogens, including multi-antibiotic-resistant strains. Solvents with different polarities were used to extract different complements of phytochemicals from T. canescens leaves. Methanolic and aqueous extracts exhibited substantial antimicrobial activity against various pathogens, including those that are multidrug-resistant strains. When combined with some selected clinical antibiotics, some extracts potentiated the antibacterial inhibitory activity. This study identified two synergistic, eleven additive, eleven non-interactive and eight antagonistic interactions. The toxicities of the plant extracts were examined in the Artemia franciscana nauplii assay and were found to be non-toxic, except the aqueous extract, which showed toxicity. Metabolomic liquid chromatography-mass spectrometry (LC-MS) analyses highlighted and identified several flavonoids, including vitexin, quercetin, orientin and kaempferol, as well as the tannins ellagic acid and pyrogallol, which may contribute to the antibacterial activities observed herein. The possible mechanism of action of these extracts was further explored in this study.

Keywords: Terminalia canescens; antibiotic-resistance; ESBL; MRSA; flavonoid; tannin

1. Introduction

Recent increases in bacterial antimicrobial resistance (AMR) have resulted in increased mortality and morbidity globally [1]. Multidrug resistance (MDR) in Gram-negative and Gram-positive bacteria has decreased the effectiveness of existing broad-spectrum antibiotics [1]. The increase in AMR has led to the loss of affordable and effective treatments for infections as well as decreased efficacies of penicillin and oxacillin for treating *Staphylococcal* infections, sulphonamides and ampicillin for urinary tract infections, and penicillin and fluoroquinolones for combating gonorrhea [2]. AMR has serious implications for public health and social and economic implications. It affects both hospital-acquired infections, including methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant *S. aureus* and vancomycin-resistant *Enterococci*, and extended-spectrum β -lactamase (ESBL) enzyme producing Gram-negative bacteria. AMR impacts community-acquired infections, including pneumonia, typhoid fever and *Streptococcal* infections. AMR leads to longer hospital stays and increases the cost of treatment, which increases the economic impact on the community [3]. The combination of a heavy disease burden, poor sanitation and the improper use of antibiotics contributes to the development of AMR. Numerous organizations,



Citation: Zai, M.J.; Cheesman, M.J.; Cock, I.E. Phytochemical Evaluation of *Terminalia canescens* DC. Radlk. Extracts with Antibacterial and Antibiotic Potentiation Activities against Selected β-Lactam Drug-Resistant Bacteria. *Molecules* **2024**, *29*, 1385. https://doi.org/ 10.3390/molecules29061385

Academic Editors: Jean-Marc Sabatier and Rossella Grande

Received: 23 January 2024 Revised: 27 February 2024 Accepted: 18 March 2024 Published: 20 March 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). including the Infectious Disease Society of America (IDSA), the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO) and the World Economic Forum (WEF) have highlighted antibiotic resistance as a major concern to public health globally [4,5]. Indeed, WHO have proposed a global action plan to fight the problem of AMR [6].

There has been a substantial increase in research efforts aimed at developing novel treatments against multidrug-resistant (MDR) and extensively resistant bacterial species. In recent times, traditional and herbal medicines have attracted considerable attention as potential candidates for new drug discovery targets [7]. The increasing interest in medicinal plants is supported by a mounting body of evidence reporting their antimicrobial properties, and the ability of some plant extracts to potentiate the efficacies of some clinical antibiotics [8]. The genus *Terminalia* consists of approximately 250 species, with a significant number of its species used traditionally to treat diverse ailments. These therapeutic uses include (but are not limited to) diarrhea, headache, gastric ulcers, heart disease, skin disease and bacterial infections [9]. Phytochemical investigations into several *Terminalia* species have identified several phytochemical classes, including tannins, triterpenes and glycoside derivatives, along with flavonoids and other polyphenolic compounds [10]. This variety of phytochemicals may contribute to the medicinal properties of *Terminalia* species, the therapeutic potential of *Terminalia canescens* DC. Radlk remains unexplored.

This study assesses the bacterial-growth inhibitory activity of *T. canescens* leaf extracts against a panel of bacterial spp. sensitive to β -lactam antibiotics, as well as antibiotic-resistant strains. The bacteria examined in this study included *K. pneumoniae* and ESBL *K. pneumoniae*, *S. aureus* and MRSA, as well as *E. coli* and ESBL *E. coli*. Our focus was on β -lactam resistance, although the analyzed strains also exhibit resistance to multiple other classes of antibiotics [11]. Furthermore, antimicrobial activity of *T. canescens* extracts was also tested in combination with conventional antibiotics to determine whether plant extracts potentiate the activity of the antibiotics in the combination. The rapid increase in β -lactam resistance pathogens is alarming considering our historical reliance on this class of antibiotics as broad-spectrum antibiotics. Additionally, high performance liquid chromatography–mass spectrometry (LC-MS) analysis of the *T. canescens* extracts was used to identify notable compounds in the extracts. The extracts' toxicities were evaluated by an *Artemia franciscana* (ALA) nauplii toxicity assay.

2. Results

2.1. Antimicrobial Susceptibility Studies

Powdered *T. canescens* leaves were extracted using solvents of varying polarities, then dried and resuspended in 10 mL of 1% DMSO, resulting in concentrations of 30.7, 16.4, and 4.3 mg/mL for the methanolic, water, and ethyl acetate extracts, respectively. The antimicrobial activity of each extract was initially examined in a panel of bacterial species on agar plates by disc diffusion assays (Figure 1) measured as zones of inhibition (ZOIs). These assays were included to provide an approximation of bacterial infections on solid surfaces. Liquid dilution assays (Table 1) were also used to quantify the antibacterial potency of the extracts by determining minimum inhibitory concentrations (MICs). The *T. canescens* methanol (TCAM) and *T. canescens* water (TCAW) extracts both inhibited the growth of all of the antibiotic-sensitive and antibiotic-resistant bacterial strains tested herein. In contrast, the *T. canescens* ethyl acetate extract (TCAE) did not inhibit the growth of any bacterial species in either the disc diffusion assay or liquid dilution assays. Notably, the methanolic extract had similar activities against the antibiotic-sensitive *K. pneumoniae* and the ESBL *K. pneumoniae* strains (MIC = 960 μ g/mL).



Figure 1. Antimicrobial effects of the *T. canescens* leaf extracts against (**A**) *K. pneumoniae*, (**B**) ESBL *K. pneumoniae*, (**C**) *S. aureus*, (**D**) MRSA, (**E**) *E. coli* and (**F**) ESBL *E. coli*. TCAM = *Terminalia canescens* methanol, TCAW = *Terminalia canescens* water, TCAE = *Terminalia canescens* ethyl acetate extract. Positive controls = ampicillin (AMP; 2 µg) and erythromycin (ERTH; 10 µg). Negative control (NC) = water. Results are expressed as mean zones of inhibition of three independent replicates \pm SEM (*n* = 3). * indicates that the results are significantly different to the negative control (*p* < 0.01).

Table 1. MIC values (μ g/mL) of plant extracts and conventional antibiotics against the bacteria tested in this study.

Extract and Antibiotic	MIC (µg/mL)						
Extract and Antibiotic	E. coli	ESBL E. coli	S. aureus	MRSA	K. pneumoniae	ESBL K. pneumoniae	
TCAM	1919	1919	960	1919	960	960	
TCAW	2050	2050	1025	2050	2050	2050	
TCAE	-	-	-	-	-	-	
Tetracycline	-	-	1.25	-	-	-	
Chloramphenicol	-	-	0.31	-	1.25	1.25	
Ciprofloxacin	2.5	-	0.62	2.5	2.5	1.25	
Gentamicin	0.039	0.039	0.03	0.03	0.03	0.03	
Erythromycin	-	-	1.25	-	2.5	-	
Negative control	-	-	-	-	-	-	

TCAM = *Terminalia canescens* methanol extract, TCAW = *Terminalia canescens* water extract, and TCAE = *Terminalia canescens* ethyl acetate extract; - indicates no inhibition was observed at any concentration tested. MIC values of triplicate determinations (n = 3) are shown and are expressed in units of µg/mL.

2.2. Calculation of Fractional Inhibitory Concentration

The *T. canescens* leaf extracts were also tested in combination with a panel of conventional antibiotics to evaluate the effects of the extracts on the antibiotics function. Several classes of interactions were observed when the combinations were tested against antibiotic-sensitive and antibiotic-resistant *K. pneumoniae*, *S. aureus* and *E. coli* (Table 2). Notably, two combinations, comprising TCAM in combination with ciprofloxacin against *E. coli*, and TCAW in combination with ciprofloxacin against *K. pneumoniae*, exhibited synergistic effects. Therefore, there would be substantial advantage in using these combinations against these pathogens, rather than using either the extract or antibiotic component alone. Additionally, eleven combinations were antagonistic. As the antagonistic combinations have decreased efficacy compared to using either component separately, these combinations should be avoided against those bacteria.

Bacteria	Extract	Tetracycline	Chloramphenicol	Ciprofloxacin	Gentamicin	Erythromycin
E. coli	TCAM	-	-	0.31	2.13	-
	TCAW	-	-	0.75	2.1	
	TCAE	-	-	-	-	-
	TCAM	-	-	-	2.72	-
ESBL E. coli	TCAW	-	-	-	2.66	-
_	TCAE	-	-	-	-	-
S. aureus	TCAM	0.63	2	1.50	<u>5.70</u>	0.63
	TCAW	0.75	3	2	<u>22</u>	1.5
	TCAE	-	-	-	-	-
MRSA	TCAM	-	-	0.62	<u>5.45</u>	-
	TCAW	-	-	0.75	<u>5.32</u>	-
	TCAE	-	-	-	-	-
K. pneumoniae	TCAM	-	1.25	1.12	<u>11.4</u>	0.56
	TCAW	-	1	0.37	<u>10.6</u>	0.75
	TCAE	-	-	-	-	-
ESBL K. – pneumoniae _	TCAM	-	1.25	-	<u>5.70</u>	-
	TCAW	-	1	-	5.33	-
	TCAE	-	-	-	-	-

Table 2. \sum FIC values for interactions between plant extracts and antibiotics.

 \sum FIC values of plant extracts in combination with conventional antibiotics against sensitive and resistant strains of *E. coli, S. aureus* and *K. pneumoniae*. TCAM = *Terminalia canescens* methanol extract, TCAW = *Terminalia canescens* water extract, TCAE = *Terminalia canescens* ethyl acetate extract; **Synergy** = \leq 0.5; *Additive* = > 0.5–1.0, Indifferent = >1.0– \leq 4; Antagonistic = >4.0. FIC values were evaluated in duplicate (*n* = 2). - indicates no inhibition at any concentration tested.

2.3. Evaluation of Extract and Antibiotic Synergistic Interactions at Different Ratios

Two combinations of extracts and antibiotics were synergistic: TCAM combined with ciprofloxacin and the combination of TCAW and ciprofloxacin (Table 2). Therefore, multiple extract/antibiotic ratios were tested using isobolograms and the fractional inhibitory concentrations were plotted to identify the synergistic ratios. Only the synergistic and additive combinations are displayed in the isobolograms (Figure 2). The TCAM and ciprofloxacin combination exhibited synergy against *E. coli*, although only in ratios consisting of 10–60% extract. In contrast, the TCAW and ciprofloxacin combination produced synergistic interactions against *K. pneumonia*, although only at ratios containing 40–90% extract, while ratios containing 10–30% extract produce additive effects. Ratios that were non-interactive have

no additional benefits over the individual components alone and hence were not included in the isobolograms.

2.4. Identification of Compounds in the TCAM and TCAW Extracts

TCAM and TCAW extracts showed the greatest antimicrobial activity in the disc diffusion susceptibility tests, as well as in the liquid dilution assays, and were therefore deemed to be the most promising extracts for phytochemical separation and identification studies. Optimized parameters that were previously developed in our group for high-performance liquid chromatography–mass spectrometry (HPLC-MS) [12] were used to analyze the metabolomic profile of these extracts, with a focus on flavonoid and tannin components. The resulting total compound chromatograms in positive ionization mode for TCAM and TCAW are shown in Figures 3A and 3B, respectively. The analysis identified a variety of compounds in the TCAM and TCAW extracts, of which the flavonoids and tannin components are listed in Table 3.



Figure 2. (A) Isobologram analysis of the TCAM and ciprofloxacin combination when tested at multiple ratios against *E. coli;* (B) Isobologram of ratios of TCAW extract in combination with ciprofloxacin against *K. pneumoniae*. FIC values are displayed as the means of two independent repeats (n = 2). Ratio = % extract: % antibiotic. Values below the 0.5/0.5 line represent synergy; the segment between the 0.5/0.5 and 1/1 lines represents additive interactions. Only the synergistic and additive ratios are displayed in these graphs.



Figure 3. Total compound LC-MS chromatograms in positive ionization mode of (**A**) TCAM (*T. canescens* methanol) and (**B**) TCAW (*Terminalia canescens* water) extracts.

2.5. Quantification of Toxicity

The toxicity of the extracts (across the range 125 to 1000 μ g/mL) was screened using *Artemia franciscana* nauplii (ALA) toxicity assays. Extracts tested at concentrations that induced <50% mortality were deemed to be non-toxic at those concentrations. Extract concentrations that produced >50% mortality were diluted until a concentration that induced <50% mortality was identified. The methanol and ethyl acetate extracts were both non-toxic (<50% mortality at 1000 μ g/mL). In contrast, the water extract induced >50% toxicity at 1000 μ g/mL, and was then further diluted to determine the LC₅₀. For the aqueous extract, the LC₅₀ was calculated to be 500 μ g/mL and hence was classified as nontoxic. In contrast, the positive control (2 mg/mL potassium dichromate) induced 100% mortality, while the negative control (seawater) induced 0% mortality.

	Retention Time (Min) Empirical Formula		Molecular Mass	Putative Identification	Relative Abundance (% Total Area)	
					TCAM	TCAW
	6.18	$C_{21}H_{20}O_{10}$	432	Vitexin	1.38	
-	7.07	$C_{21}H_{20}O_{11}$	448	Trifolin	3.82	
- Flavonoids	6.31	$C_{21}H_{20}O_{12}$	464	Quercitin-3β-D-glucoside	0.99	
	6.36	C ₂₇ H ₃₀ O ₁₆	610	Quercitin 3-O-rhamnoside-7 -O-glucoside	0.50	
-	6.31	C ₁₅ H ₁₀ O ₇	302	Quercetin	0.64	
-	5.54	C ₂₁ H ₂₀ O ₁₁	448	Orientin	7.91	
-	7.14	C ₂₇ H ₃₀ O ₁₅	594	Nictoflorin	0.98	
-	7.13	$C_{15}H_{10}O_{6}$	286	Kaempferol	0.19	
	7.24	C ₁₆ H ₁₂ O ₇	316	Isorhamnetin	0.31	
	8.51	$C_{22}H_{20}O_{12}$	476	Hispidulin 7-glucuronide	2.53	
	7.07	C ₁₅ H ₁₀ O ₆	286	Fisetin	1.10	
	6.10	C ₂₁ H ₁₈ O ₁₄	494	8-Hydroxytricetin 7-glucuronide	0.04	
	7.25	C ₂₂ H ₂₂ O ₁₂	478	5,7-Dihydroxy-2-(4-hydroxy-3- methoxyphenyl)-3-{[3,4,5- trihydroxy-6- (hydroxymethyl)oxan-2-yl]oxy}- 4H-chromen-4-one	0.43	
	6.88	$C_{21}H_{20}O_{11}$	448	4-(3,4-Dihydroxyphenyl)-7- hydroxy-5-{[(2 <i>S</i> ,3 <i>R</i> ,4 <i>S</i> ,5 <i>S</i> ,6 <i>R</i>)- 3,4,5-trihydroxy-6- (hydroxymethyl)oxan-2-yl]oxy}- 2 <i>H</i> -chromen-2-one	3.46	
	6.19	$C_{15}H_{10}O_9$	334	3,5,6,7,2',3',4'- Heptahydroxyflavone	0.08	
	5.27	$C_{20}H_{18}O_{13}$	466	2-(3,4-Dihydroxyphenyl)-3,5,7- trihydroxy-8-{[(2 <i>R</i> ,3 <i>R</i> ,4 <i>S</i> ,5 <i>S</i> ,6 <i>R</i>)- 3,4,5,6-tetrahydroxytetrahydro- 2 <i>H</i> -pyran-2-yl]oxy}-4 <i>H</i> -chromen- 4-one	0.04	
	6.58	C ₂₈ H ₂₄ O ₁₄	584	2"-O-Galloylisovitexin	0.19	

Table 3. Qualitative analysis of LC-MS of TCAM and TCAW.

	Retention Time (Min)	Empirical Formula	Molecular Mass	Putative Identification	Relative Abundance (% Total Area)	
				-	TCAM	TCAW
	7.43	$C_{21}H_{18}O_{12}$	462	(25,35,45,5R,6S)-6-{[5,7- Dihydroxy-2-(4-hydroxyphenyl)- 4-oxo-4H-chromen-3-yl]oxy}- 3,4,5-trihydroxyoxane-2- carboxylic acid	0.13	
	9	$C_{15}H_{10}O_7$	302	Quercetin		0.18
	6.29	$C_{21}H_{20}O_{11}$	448	Orientin		9.77
	0.35	$C_{21}H_{20}O_{14}$	496	Hibiscetin 3-glucoside		0.49
	13.70	C ₁₈ H ₁₄ O ₉	374	Gossypetin 7-methyl ether 8-acetate		0.02
	10.03	C ₁₅ H ₁₀ O ₆	286	Fisetin		0.11
	7.63	$C_{20}H_{22}O_5$	342	Brosimacutin C		0.02
	10.61	C ₁₆ H ₁₂ O ₇	316	2-(3,4-dihydroxyphenyl)-3,5,7- trihydroxy-6-methyl-4 <i>H</i> - chromen-4-one		0.17
	7.35	$C_{21}H_{20}O_{10}$	432	1,5-Anhydro-1-[5,7-dihydroxy-3- (4-hydroxyphenyl)-4-oxo-4H- chromen-8-yl]hexitol		1.03
	6.95	C ₂₈ H ₂₄ O ₁₅	600	(2 <i>S</i> ,3 <i>R</i> ,4 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-2-{[2-(3,4- Dihydroxyphenyl)-5,7-dihydroxy- 4-oxo-4 <i>H</i> -chromen-3-yl]oxy}-3,5- dihydroxy-6-methyloxan-4-yl 3,4,5-trihydroxybenzoate		0.01
Tannins	6.09	$C_{14}H_{6}O_{8}$	303	Ellagic acid (Isomer 1)	3.84	
	7.47	$C_{14}H_{6}O_{8}$	303	Ellagic acid (Isomer 2)		4.06
	1.64	C ₆ H ₆ O ₃	126	Pyrogallol		2.23

Tabl	le 3.	Cont.

3. Discussion

Aqueous and methanolic T. canescens leaf extracts inhibited the growth of all six bacterial species tested in the disc diffusion and the liquid dilution assay, including the antibiotic-resistant strains. The methanolic extract was generally a substantially more potent inhibitor of bacterial growth. In contrast, the ethyl acetate extract failed to inhibit the activity of any bacterial strain. The difference in the antibacterial activity of these extracts may be due to the specific phytochemicals extracted from T. canescens using solvents of different polarities. Polar solvents generally extract more phytochemicals from plants and in greater abundance compared to lower-polarity solvents [13]. These compositional differences may account for the varying levels of antibacterial activity observed between the disc diffusion and the liquid dilution assay. Phytochemicals with lower polarity and/or larger molecular sizes are hindered while diffusing through solid-phase agar, potentially influencing the perceived antimicrobial efficacy of the extracts in disc diffusion assays [13]. Additionally, the volatile extract components may evaporate from the surfaces of agar gel, leading to decreases in their concentration in the assay, and consequently decreases in their apparent effectiveness [14]. Disc diffusion assays are also influenced by the solubility of the extracted compounds in aqueous solutions, with polar compounds diffusing faster than less soluble compounds. Indeed, the low-solubility compounds may remain concentrated around the disc, which may result in underestimating the MIC values of the extracts [15]. The liquid dilution assay is regarded as more sensitive than the disc diffusion assay, as it is less susceptible to the impacts of compound polarity and size.

Interestingly, the *T. canescens* extracts showed similar inhibitory effects against bacterial species that were resistant to bacteria, compared to their susceptible counterparts. This indicates that compounds present in the *T. canescens* extracts are relatively unaffected by the MRSA and ESBL antibiotic-resistance mechanisms. Therefore, *T. canescens* extract components function via mechanisms that are distinct from those targeted by the antibiotics to which these strains are resistant, particularly the β -lactam antibiotics. Alternatively, specific extract constituents may block the bacterial resistance mechanisms. This is promising, as the antibiotic-resistant bacterial strains examined in this study exhibited significantly diminished susceptibilities to various antibiotics of diverse classes, including tetracyclines, aminoglycosides, fluoroquinolones, sulfonamides, macrolides and β -lactams. Furthermore, the efficacies of *T. canescens* extracts against both Gram-negative and Gram-positive bacteria highlights their potential as broad-spectrum antibiotics. To comprehensively assess their antibiotic potential, future studies should screen the *T. canescens* extracts against a more comprehensive panel of pathogenic bacteria, including other MDR strains.

There is substantial recent interest in the use of plant extracts for potentiating clinical antibiotics against diverse bacterial strains [16]. We observed two synergistic, eleven additive, eleven non-interactive, and eight antagonistic interactions in this study. Synergistic combinations possess substantially enhanced antibacterial effectiveness compared to additive interactions, which also amplify antibiotic potency, albeit to a lesser extent than synergistic interactions. Synergy was observed when combinations of TCAM extract and ciprofloxacin were tested against *E. coli*, and for the combination of TCAW extract and ciprofloxacin against K. pneumoniae. Ciprofloxacin targets the alpha subunit of DNA gyrase and prevents it from supercoiling the bacterial DNA which prevents the replication DNA [17]. The plant extracts tested in this study may contain components that block the resistance mechanism of ciprofloxacin, although this remains to be verified. Additionally, the TCAM and TCAE extracts were determined to be nontoxic in the ALA toxicity assay, while TCAW was found to be toxic. Notably, brine shrimp assays are sensitive to changes in pH [18], and this may provide erroneous results. Acidic pH can negatively impact the rate of mitochondrial protein synthesis and may become fatal to the development and growth of nauplii [18]. Water extracts higher levels of organic acids and other acidic compounds than do many other solvents, which may account for the higher levels of toxicity noted for the aqueous extract in our study, compared to the methanolic extract. Therefore, it is suggested that future studies should determine the toxicity of T. canescens extracts using human dermal fibroblast toxicity assay, which is a more robust toxicity assay, and not influenced by the pH levels. Conversely, non-interactive combinations neither boost nor diminish the antibacterial effects of the extract or antibiotic components, indicating that they are safe for simultaneous use, despite providing no additional benefit over using either component alone. Notably, antagonistic combinations reduce the antibacterial activity of combinations of extracts and antibiotics, and thus should be avoided.

Previous studies in our group have employed LC-MS metabolomics profile analyses to characterize the phytochemical composition of several *Terminalia* species. These analyses aimed to identify and quantify the relative abundances of phyto-constituents within the plant extracts [19]. Several different classes of compounds were identified in *Terminalia* spp. leaf extracts, including the tannins gallic acid, ellagic acid and chebulic acid, and multiple flavonoids. Tannins and flavonoids were also identified in our study in the methanol and aqueous *T. canescens* extracts (Table 3). Specifically, our study detected the flavonoids vitexin (Figure 4A), trifolin (Figure 4B), quercetin (Figure 4C), orientin (Figure 4D), nictoflorin (Figure 4E), kaempferol (Figure 4F), isorhamnetin (Figure 4G) and fisetin (Figure 4H), as well as the tannins ellagic acid (Figure 4I) and pyrogallol (Figure 4J). The antimicrobial properties of flavonoids are well documented against a range of bacterial pathogens [20]. With the increasing prevalence of antibiotic-resistant infections, flavonoids have potential

as antibiotic alternatives, as well as in their capacity to overcome or bypass some bacterial resistance mechanisms and therefore potentiate the activity of other compounds.

The therapeutic properties of flavonoids in other species have been well documented. For example, Tagetes minuta L., which contains the flavonoid quercetagetin-7-arabinzylgalactoside, is widely used in Argentinean traditional medicine to treat numerous infectious diseases [21]. Studies have also documented the antibacterial activity of flavonoid-rich plant extracts, including Capsella spp. [22], Hypericum spp. [23] and Chromolaena spp. [22]. Tripleurospermum disciforme (C.A.Mey.) Sch.Bip. is used to treat of multiple bacterial diseases, and as a disinfectant in Iranian traditional medicine. This species contains relatively high levels of several flavonoids, including quercetin, kaempferol, and their respective glycosides. Quercetin and kaempferol were also detected in the T. canescens extracts in our study (Table 3). The antimicrobial properties exhibited by numerous plant-derived flavonoids work through distinct mechanisms compared to conventional drugs, suggesting their potential significance in augmenting antimicrobial therapeutic approaches [24]. Flavonoids (especially catechins) have been reported to have noteworthy antimicrobial properties against both Gram-negative and Gram-positive bacteria. Flavonoids interact with lipid membrane bilayers via two mechanisms [25]. They partition lower polarity compounds into the hydrophobic inner region of the membrane bilayer. Alternatively, flavonoids may induce hydrogen bond formation between the polar head groups of the membrane phospholipids and the flavonoids at the membrane surface. These interactions between phospholipid and flavonoid components induce conformational changes in membrane proteins, including thickness fluctuations, thereby indirectly modulating the function and distribution of membrane proteins.

Tannins also have inhibitory effects on the growth of a diverse range of microorganisms, including fungi, bacteria and yeasts [26]. Tannins function as multidentate ligands, binding proteins through hydrophobic interactions and hydrogen bonds, thereby inhibiting bacterial metabolism [27]. The MICs of tannins against a variety of different pathogens have been reported to be in the range of 61.5– $3200 \ \mu\text{g/mL}$ [28]. The formation of biofilms is believed to be linked to a substantial proportion of persistent and chronic bacterial infections, with estimates indicating that more than 60% of all bacterial infections result in biofilm development [29]. Extracts that are rich in ellagic acid, which was identified in our study (Table 3), reduce the biofilm activity of *E. coli* and *C. albicans* [30]. In contrast to conventional antibiotics, which generally eliminate bacteria, ellagic acid seems to modify bacterial behaviour by selectively inhibiting biofilm formation, with minimal impact on planktonic bacteria. Compounds with such characteristics may exhibit reduced susceptibility to the development of bacterial resistance, although further studies are needed to confirm this.

The flavonoids and tannins identified in our study may possess intrinsic antimicrobial properties, or alternatively they may potentiate the effects of other T. canescens extract components (and some conventional antibiotics). However, additional studies are required to reveal their effects and the antibacterial mechanisms. Future studies should explore these compounds as potential frameworks for new antibiotic therapies, or as potentiating compounds to enhance the efficacy of existing antibiotics. The T. canescens extracts tested in our study were effective against both antibiotic-resistant and susceptible strains, a characteristic that is necessary for the development of novel antibiotic drugs. Notably, some extract compounds remained unidentified using LC-MS metabolomic profiling analysis, and these compounds may also contribute to the activity of these extracts. Additionally, lower polarity compounds may not have been detected, and some volatile components may have evaporated during the extraction and/or assay processes. Therefore, further phytochemical studies utilizing different methods (e.g., GC-MS) are required for a complete evaluation of the extracts' compositions. Importantly, the extracts were non-toxic in the Artemia nauplii assay, indicating their safety for antibiotic use. However, testing the extracts against an extensive panel of human cell lines is required to further validate their lack of toxicity and therefore to evaluate their safety for medicinal use.

Figure 4. (A) Vitexin, (B) trifolin, (C) quercetin, (D) orientin, (E) nictoflorin, (F) kaempferol, (G) isorhamnetin, (H) fisetin, (I) ellagic acid and (J) pyrogallol.

The studies presented herein quantify the effects of these *T. canescens* extracts against planktonic cells in liquid dilution assays. Notably, many bacteria form biofilms as a protective mechanism and antibiotic extracts and isolated compounds may be substantially less effective against biofilm bacteria than against planktonic bacteria. The solid phase disc diffusion assays presented in this study were included as an approximation of the effects of the extracts against bacteria attached to solid surfaces. However, these effects should be confirmed in future studies using specific biofilm assay models. Additionally, future studies are required to evaluate the antibacterial effects (bactericidal and/or bacteriostatic) of the extract components, and to determine the specific mechanisms.

4. Materials and Methods

4.1. Materials

All chemicals and reagents used in the studies described herein were AR grade and unless otherwise stated were obtained from Ajax Fine-Chemicals Ltd., Taren Point, Australia. Mueller-Hinton broth and agar were purchased from Oxoid Ltd., Thebarton, Australia. All other chemicals and reagents were acquired from Sigma Aldrich, Bayswater, Australia unless otherwise stated.

4.2. Plant Collection and Extraction

Terminalia canescens leaves were collected from James Cook University, Cairns by Dr Phurpa Wangchuk and provided for this study. A voucher specimen (GU_TcanJCU_2022) is stored in the School of Environment and Sciences, Griffith University, Australia. A Sunbeam food dehydrator was used to dry the leaves, which were subsequently ground into a fine powder. Methanol, water, or ethyl acetate (50 mL each) were added to individual tubes containing one gram dried and powdered leaf. Extraction of plant material was carried out by maceration for 24 h at room temperature. Whatman No. 54 filter paper was then used to remove particulates from the extracts. A vacuum oven was used to dry the extracts and the mass or dried extract was determined. The dried extracts were reconstituted by adding 100 μ L of DMSO to partially dissolve the pellet and increased to 10 mL total volume using sterile deionized water. A syringe-driven filter (0.22 μ m; Millipore North Ryde, Australia Pty Ltd., Macquarie Park, Australia) was used to filter the extracts. The extracts were then stored at 4 °C till further use.

4.3. Antibacterial Studies

4.3.1. Growth of Bacterial Cultures

Initially, bacterial stock cultures were individually streaked onto Muller–Hinton agar plates and incubated for 24 h at 37 °C. A single bacterial colony was isolated and transferred into Muller–Hinton broth (50 mL) and incubated at 37 °C until the bacterial log growth phase was achieved. The purity of the culture was ensured by re-streaking the culture onto fresh Muller–Hinton agar plates.

4.3.2. Disc Diffusion Assay

Standard methods were followed to examine the antibiotic susceptibility of each bacterial strain by using standard Kirby–Bauer disc diffusion assays [12].

4.3.3. Liquid Microdilution MIC Assay

The MIC values of the plant extract and antibiotics were determined through liquid microdilution assays using standard methods [12].

4.4. Determination of Combinational Effects and Optimal Ratios through Isobologram

The interaction effects between the plant extracts and selected conventional antibiotics were studied in 1:1 ratios of the components. The MICs were determined using the same method described in Section 4.3.3. The following formula was then used to calculate the fractional inhibitory concentration (FIC) values:

FIC (E) = (MIC of E in combination with A)/MIC of E alone.

FIC (A) = (MIC of A in combination with E)/MIC of A alone.

$$\sum$$
 FIC = FIC (E) + FIC (A).

where E = plant extract; and A = antibiotic. \sum FIC values ≤ 0.5 were termed as synergistic, $>0.5-\leq1.0$ were categorized as additive, values $>1.0-\leq4.0$ were classed as non-interactive, and \sum FIC values >4.0 were designated as antagonistic.

The combinations which yielded synergistic interactions were subsequently examined at various ratios to determine the ideal ratio(s) at which synergy occurs. The same protocol described in Section 4.3.3. was followed, although a range of ratios of the extract–antibiotic combination were tested. The ratios ranged from 100% antibiotic to 0% extract, with a 10% reduction in increments, and from 0% antibiotics to 100% extract, with a 10% increase in increments. The assay was performed in duplicate, and the resulting data was used for the calculation of FIC values. Isobolograms were plotted and used to identify the ratios that produced synergistic interactions occurring between plant extract (E) and antibiotic (A).

4.5. Non-Targeted Head Space LC-MS Conditions for Quantitative Analysis

The identification of different compounds in the extracts was achieved by using non-targeted headspace metabolic profiling. Liquid chromatography–mass spectrometry (LC-MS) analysis was conducted using standard methods previously developed in or laboratory [31]. Putative compound identification was accomplished through molecular annotation against the ChemSpider, CyanoMetDB, mzVault, mzCloud and Global Natural Product Social Molecular Networking (GNPS) databases, as well as via comparisons with published data.

4.6. Toxicity Studies

The toxicity of plant extracts was determined by employing *Artemia franciscana* nauplii lethality assays (ALA) using standard methods [12].

5. Conclusions

The urgent need to address AMR has led to a substantial increase in the number of studies testing extracts and natural products as sources for novel antibiotic therapies. Our study reports that *T. canescens* has inhibited the activity of MDR and ESBL bacteria as effectively as in the cases of the sensitive strains. This shows that plant extract phytochemicals may have novel and/or unstudied antimicrobial mechanisms. Also, some of the compounds identified herein may contribute to the antimicrobial activities. Future studies are planned to investigate the antibacterial properties of these compounds. Additionally, studies should also further explore the effectiveness of these compounds to potentiate conventional antibiotics by determining the potentiation mechanisms.

Author Contributions: Conceptualization: M.J.Z., M.J.C. and I.E.C.; methodology: M.J.Z., M.J.C. and I.E.C.; validation, formal analysis, data curation: M.J.Z.; writing—original draft preparation: M.J.Z.; writing—review and editing, supervision: M.J.C. and I.E.C.; project administration and funding acquisition: I.E.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The work presented in this study complies with the *Australian code of practice for the care and use of animals for scientific purposes* [31], which outlines the requirement for "replacement", "reduction" and the "refinement" of the use of animals for scientific purposes. The term "replacement" in this code is used with the intention of eliminating the use of vertebrates in experiments. The only organisms used in our experiments were invertebrates and microbial organisms. The use of these organisms does not require ethics approval under this code or through Griffith University.

Informed Consent Statement: Not applicable.

Data Availability Statement: All data are available from the corresponding author upon reasonable request.

Conflicts of Interest: The authors declare no conflicts of interest.

References

- 1. Akova, M. Epidemiology of antimicrobial resistance in bloodstream infections. *Virulence* 2016, 7, 252–266. [CrossRef]
- 2. Finch, R.G.; Metlay, J.P.; Davey, P.G.; Baker, L.J. Educational interventions to improve antibiotic use in the community: Report from the International Forum on Antibiotic Resistance (IFAR) colloquium, 2002. *Lancet Infect. Dis.* **2004**, *4*, 44–53. [CrossRef]
- 3. Holmberg, S.D.; Solomon, S.L.; Blake, P.A. Health and economic impacts of antimicrobial resistance. *Rev. Infect. Dis.* **1987**, 9, 1065–1078. [CrossRef]
- 4. Michael, C.A.; Dominey-Howes, D.; Labbate, M. The antimicrobial resistance crisis: Causes, consequences, and management. *Front. Public Health* **2014**, *2*, 145. [CrossRef]
- 5. Spellberg, B.; Srinivasan, A.; Chambers, H.F. New societal approaches to empowering antibiotic stewardship. *JAMA* **2016**, 315, 1229–1230. [CrossRef]
- 6. Hoffman, S.J.; Caleo, G.M.; Daulaire, N.; Elbe, S.; Matsoso, P.; Mossialos, E.; Rizvi, Z.; Røttingen, J.-A. Strategies for achieving global collective action on antimicrobial resistance. *Bull. World Health Organ.* **2015**, *93*, 867–876. [CrossRef] [PubMed]

- 7. Chandra, H.; Bishnoi, P.; Yadav, A.; Patni, B.; Mishra, A.P.; Nautiyal, A.R. Antimicrobial resistance and the alternative resources with special emphasis on plant-based antimicrobials—A review. *Plants* **2017**, *6*, 16. [CrossRef] [PubMed]
- 8. Silva, D.M.; COSTA, P.A.; Ribon, A.O.; Purgato, G.A.; Gaspar, D.-M.; Diaz, M.A. Plant extracts display synergism with different classes of antibiotics. *An. Acad. Bras. Ciências* **2019**, *91*, e20180117. [CrossRef] [PubMed]
- Eloff, J.; Katerere, D.; McGaw, L. The biological activity and chemistry of the southern African Combretaceae. J. Ethnopharmacol. 2008, 119, 686–699. [CrossRef] [PubMed]
- 10. Garcez, F.R.; Garcez, W.S.; Miguel, D.L.; Serea, A.A.; Prado, F.C. Chemical constituents from *Terminalia glabrescens*. J. Braz. Chem. Soc. 2003, 14, 461–465. [CrossRef]
- 11. Cheesman, M.J.; White, A.; Matthews, B.; Cock, I.E. *Terminalia ferdinandiana* fruit and leaf extracts inhibit methicillin-resistant Staphylococcus aureus growth. *Planta Medica* 2019, *85*, 1253–1262. [CrossRef]
- 12. Zai, M.J.; Cheesman, M.J.; Cock, I.E. *Terminalia petiolaris* A.Cunn ex Benth. extracts have antibacterial activity and potentiate conventional antibiotics against β-lactam-drug-resistant bacteria. *Antibiotics* **2023**, *12*, 1643. [CrossRef] [PubMed]
- 13. Eloff, J. Which extractant should be used for the screening and isolation of antimicrobial components from plants? *J. Ethnopharmacol.* **1998**, *60*, 1–8. [CrossRef] [PubMed]
- 14. van Vuuren, S.; Viljoen, A. Plant-based antimicrobial studies-methods and approaches to study the interaction between natural products. *Planta Medica* **2011**, *77*, 1168–1182. [CrossRef] [PubMed]
- 15. Bonev, B.; Hooper, J.; Parisot, J. Principles of assessing bacterial susceptibility to antibiotics using the agar diffusion method. *J. Antimicrob. Chemother.* **2008**, *61*, 1295–1301. [CrossRef] [PubMed]
- 16. Cheesman, M.J.; Ilanko, A.; Blonk, B.; Cock, I.E. Developing new antimicrobial therapies: Are synergistic combinations of plant extracts/compounds with conventional antibiotics the solution? *Pharmacogn. Rev.* **2017**, *11*, 57.
- 17. Rayan, P.; Matthews, B.; McDonnell, P.; Cock, I. *Terminalia ferdinandiana* extracts as inhibitors of *Giardia duodenalis* proliferation: A new treatment for giardiasis. *Parasitol. Res.* **2015**, *114*, 2611–2620. [CrossRef]
- 18. Kwast, K.E.; Hand, S.C. Oxygen and pH regulation of protein synthesis in mitochondria from *Artemia franciscana* embryos. *Biochem. J.* **1996**, *313*, 207–213. [CrossRef]
- 19. Cushnie, T.T.; Lamb, A.J. Antimicrobial activity of flavonoids. Int. J. Antimicrob. Agents 2005, 26, 343–356. [CrossRef]
- 20. Tereschuk, M.a.L.; Riera, M.V.; Castro, G.R.; Abdala, L.R. Antimicrobial activity of flavonoids from leaves of *Tagetes minuta*. *J. Ethnopharmacol.* **1997**, *56*, 227–232. [CrossRef]
- 21. LeBel, M. Ciprofloxacin: Chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. *Pharmacother. J. Hum. Pharmacol. Drug Ther.* **1988**, *8*, 3–30. [CrossRef]
- 22. El-Abyad, M.S.; Morsi, N.M.; Zaki, D.A.; Shaaban, M. Preliminary screening of some Egyptian weeds for antimicrobial activity. *Microbios* **1990**, *62*, 47–57. [PubMed]
- 23. Dall'Agnol, R.; Ferraz, A.; Bernardi, A.; Albring, D.; Nör, C.; Sarmento, L.; Lamb, L.; Hass, M.; Von Poser, G.; Schapoval, E. Antimicrobial activity of some *Hypericum* species. *Phytomedicine* **2003**, *10*, 511–516. [CrossRef] [PubMed]
- 24. Pandey, A.; Kumar, S. Perspective on plant products as antimicrobials agents: A review. Pharmacologia 2013, 4, 469–480. [CrossRef]
- 25. Tsuchiya, H. Membrane interactions of phytochemicals as their molecular mechanism applicable to the discovery of drug leads from plants. *Molecules* **2015**, *20*, 18923–18966. [CrossRef]
- 26. Scalbert, A. Antimicrobial properties of tannins. *Phytochemistry* **1991**, *30*, 3875–3883. [CrossRef]
- 27. Jöbstl, E.; Howse, J.R.; Fairclough, J.P.A.; Williamson, M.P. Noncovalent cross-linking of casein by epigallocatechin gallate characterized by single molecule force microscopy. *J. Agric. Food Chem.* **2006**, *54*, 4077–4081. [CrossRef]
- Farha, A.K.; Yang, Q.-Q.; Kim, G.; Li, H.-B.; Zhu, F.; Liu, H.-Y.; Gan, R.-Y.; Corke, H. Tannins as an alternative to antibiotics. *Food Biosci.* 2020, 38, 100751. [CrossRef]
- 29. Lewis, K. Riddle of biofilm resistance. Antimicrob. Agents Chemother. 2001, 45, 999–1007. [CrossRef]
- Bakkiyaraj, D.; Nandhini, J.R.; Malathy, B.; Pandian, S.K. The anti-biofilm potential of pomegranate (*Punica granatum* L.) extract against human bacterial and fungal pathogens. *Biofouling* 2013, 29, 929–937. [CrossRef]
- 31. NHMRC. *Australian Code of Practice for the Care and Use of Animals for Scientific Purposes;* National Health and Medical Research Council: Canberra, Australia, 2004; pp. 3–28.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.